Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)

Delayed Quote. Delayed  - 09/28 05:36:09 pm
11.45 EUR   +0.22%
09/15 ABLYNX : 15/09/2016 ablynx receives transparency notification from o..
09/15 ABLYNX : Receives transparency notification from oppenheimer funds, ..
09/06 ABLYNX : 06/09/2016 ablynx receives transparency notification from g..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/27/2011 | 07:05am CEST

GHENT, Belgium, 27 June 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it has earned a ?5 million milestone payment following Boehringer Ingelheim's decision to initiate development  with the lead Nanobody candidate that was selected in May 2010.

 

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.

 

"We are delighted that Boehringer Ingelheim is making further progress with the Nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012. This is the second milestone payment that we have received as part of our Alzheimer's research collaboration with Boehringer Ingelheim," said Dr. Edwin Moses, Chairman and CEO of Ablynx. He added: "This programme illustrates the wide applicability and advantages of our Nanobody platform in addressing diseases as complex as Alzheimer's."

 

 

For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1526010/461786.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1526010
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
09/15 ABLYNX : 15/09/2016 ablynx receives transparency notification from oppenheimer f..
09/15 ABLYNX : Receives transparency notification from oppenheimer funds, inc.
09/06 ABLYNX : 06/09/2016 ablynx receives transparency notification from gam holding a..
09/06 ABLYNX : Receives transparency notification from gam holding ag, gam internation..
08/25 ABLYNX : 25/08/2016 ablynx announces 2016 half-year results and year-to-date bus..
08/25 ABLYNX : Announces 2016 half-year results and year-to-date business update
08/22ABLYNX NV : half-yearly earnings release
08/17 ABLYNX : 17/08/2016 ablynx will announce its 2016 half year results with webcast..
08/17 ABLYNX : Will announce its 2016 half year results with webcast on 25 august 2016
08/12 ABLYNX : Receives transparency notification from adrianus van herk andvan herk i..
More news
Sector news : Biotechnology & Medical Research - NEC
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/29 Why Abbvie Won't Pull A Galapagos On Ablynx
08/25 Ablynx, My Favorite Belgian (Biotech) Stock
08/25 Ablynx's (ABLYF) CEO Edwin Moses on Q2 2016 Results - Earnings Call Transcrip..
08/25 Ablynx NV 2016 Q2 - Results - Earnings Call Slides
08/25 Ablynx NV reports H1'16 results
Advertisement
Financials (€)
Sales 2016 99,7 M
EBIT 2016 -9,95 M
Net income 2016 3,23 M
Finance 2016 39,1 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 6,59x
EV / Sales 2017 16,5x
Capitalization 696 M
More Financials
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 18,5 €
Spread / Average Target 62%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX-28.17%790
INCYTE CORPORATION-17.87%16 687
CELLTRION, INC.--.--%11 639
LONZA GROUP AG11.83%9 948
QUINTILES TRANSNATIONA..16.08%9 402
SEATTLE GENETICS, INC.26.05%7 828
More Results